Table 1.
Clinical background of studies included in the meta-analysis.
| Author | group | Tumor diameter (cm) | Gender (M/F) | Age (years) | Child-Pugh (A + B/C) | Tumor No. (Single/Multiple) | TNM staging (I + II/III + IV) | Cirrhosis | Matching | Complete necrosis rate |
|---|---|---|---|---|---|---|---|---|---|---|
| Kaibori [19] | Pre-TACE | 4.30 ± 2.13 | 35/7 | 68.1 ± 5.7 | 37 + 5/0 | 32/10 | 31/11 | 14/42 | (1)(2)(3)(4)(5)(6) | 9/42(21.42%) |
| Control | 4.86 ± 4.12 | 32/11 | 66.1 ± 10.6 | 39 + 4/0 | 32/11 | 31/12 | 11/43 | |||
| Zhou [20] | Pre-TACE | 9.0 ± 3.2 | 48/4 | 45.3 ± 9.8 | 44 + 8/0 | NR | 25/22 | 49/52 | (1)(2)(3)(4)(5)(6)(7) | 7/47(14.89%) |
| Control | 9.5 ± 3.9 | 49/7 | 46.8 ± 9.6 | 54 + 2/0 | NR | 31/25 | 50/56 | |||
| Cui [21] | Pre-TACE | 8.33 ± 4.49 | 32/12 | 48.3 ± 8.77 | 44/0 | NR | NR | NR | (1)(2)(3)(4)(5)(6)(7) | 8/44(18.18%) |
| Control | 8.16 ± 5.28 | 30/14 | 47.3 ± 8.91 | 44/0 | NR | NR | NR | |||
| Yamasaki [22] | Pre-TACE | 3.1 ± 0.8 | 50/0 | 54.9 ± 6.4 | NR | 42/4 | NR | NR | (4)(5)(6) | 16/50(32%) |
| Control | 3.3 ± 0.9 | 47/0 | 57.1 ± 4.9 | NR | 38/7 | NR | NR | |||
| Wu [23] | Pre-TACE | 14.3 ± 4.2 | 23/1 | 51.8 ± 12.4 | 22 + 2/0 | NR/4 | 4/20 | 14/24 | (1)(2)(3)(4)(5)(6)(7) | 0/24(0%) |
TACE: transarterial chemoembolization; NR: Not Reported;TNM: Tumor Node Metastasis (1) operation time; (2) blood loss; (3) postoperative morbidity; (4) perioperative mortality; (5) disease free survival; (6) overall survival; (7) combined resection of perihepatic organs.
Numbers are mean value ± standard deviation. Complete necrosis rate are measured by histopathology examination.